Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

aristo pharma gmbh - ramipril; amlodipino besilato - cÁpsula dura - 10 mg/10 mg - ramipril 10 mg; amlodipino besilato 10 mg - ramipril y amlodipino

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

aristo pharma gmbh - ramipril; amlodipino besilato - cÁpsula dura - 5 mg/10 mg - ramipril 5 mg; amlodipino besilato 10 mg - ramipril y amlodipino

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

aristo pharma gmbh - ramipril; amlodipino besilato - cÁpsula dura - 10 mg/5 mg - ramipril 10 mg; amlodipino besilato 5 mg - ramipril y amlodipino

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

aristo pharma gmbh - ramipril; amlodipino besilato - cÁpsula dura - 5 mg/5 mg - ramipril 5 mg; amlodipino besilato 5 mg - ramipril y amlodipino

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 10 mg - capsule - excipient ingredients: lactose monohydrate; titanium dioxide; gelatin; erythrosine; magnesium stearate; iron oxide black; indigo carmine; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - ? treatment of hypertension. (data are currently not available to support the use of ramipril in renovascular hypertension).,? post mi heart failure.,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mm hg or diastolic blood pressure > 90 mm hg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l; hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 10 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; pregelatinised maize starch; sodium bicarbonate; microcrystalline cellulose; hypromellose - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or an antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; microcrystalline cellulose; sodium stearylfumarate; hypromellose; pregelatinised maize starch - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; pregelatinised maize starch; hypromellose; microcrystalline cellulose; sodium stearylfumarate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - ramipril + hidroclorotiazida - comprimido - 5 mg + 25 mg - ramipril 5 mg ; hidroclorotiazida 25 mg - ramipril and diuretics - genérico - duração do tratamento: longa duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - ramipril + hidroclorotiazida - comprimido - 5 mg + 25 mg - ramipril 5 mg ; hidroclorotiazida 25 mg - ramipril and diuretics - genérico - duração do tratamento: longa duração